Drug & intervention

loperamide

RxCUI 6468

Clinical trials15
Recruiting3
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Loperamide

Loperamide, sold under the brand name Imodium, among others, is a medication of the opioid receptor agonist class used to decrease the frequency of diarrhea. It is often used for this purpose in irritable bowel syndrome, inflammatory bowel disease, short bowel syndrome, Crohn's disease, and ulcerative colitis. Loperamide is taken by mouth. Common side effects include abdominal pain, constipation, sleepiness, vomiting, and dry mouth. It may increase the risk of toxic megacolon. Loperamide's safety in pregnancy is unclear, but no evidence of harm has been found. It appears to be safe in breastfeeding. It is an opioid with no significant absorption from the gut and does not cross the blood–brain barrier when used at normal doses. It works by slowing the contractions of the intestines. Loperamide was first made in 1969 and used medically in 1976. It is on the World Health Organization's List of Essential Medicines. Loperamide is available as a generic medication. In 2023, it was the 276th most commonly prescribed medication in the United States, with more than 800,000 prescriptions.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

15 shown
Rash & Diarrhea Prophylaxis With CapivasertibNCT07426822 · 2026-08-15
RECRUITING
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer PatientsNCT06892093 · 2025-08-07
RECRUITING
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer PatientsNCT04038619 · 2021-02-01
RECRUITING
Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMEDNCT05520723 · 2023-02-06
COMPLETED
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant NeratinibNCT05252988 · 2022-08-31
ACTIVE_NOT_RECRUITING
Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy SubjectsNCT05252546 · 2022-03-08
COMPLETED
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With NeratinibNCT04366713 · 2020-06-30
COMPLETED
Prevention and Treatment of Pyrrolitinib-associated DiarrheaNCT04736186 · 2020-05-16
UNKNOWN
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced MalignanciesNCT04172597 · 2019-12-23
TERMINATED
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and NeratinibNCT03094052 · 2018-10-09
COMPLETED
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast CancerNCT02441946 · 2015-08-01
COMPLETED
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and LoperamideNCT02400476 · 2015-02-01
COMPLETED
Pilot Study to Assess Dimethyl Fumarate Related GI Symptom MitigationNCT02217982 · 2014-07-01
TERMINATED
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadNCT02057133 · 2014-03-10
ACTIVE_NOT_RECRUITING
ADAM-Afatinib Diarrhea Assessment and ManagementNCT01814553 · 2013-04-01
COMPLETED

Conditions being studied

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.